{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:03:11Z","timestamp":1772834591673,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["P30AR066524"],"award-info":[{"award-number":["P30AR066524"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01 AR059742"],"award-info":[{"award-number":["R01 AR059742"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004253","name":"Quaid-i-Azam University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.taap.2022.116127","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T09:29:43Z","timestamp":1655026183000},"page":"116127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Dibutylstannanediyl (2Z,2\u2032Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK\/PPAR\u03b1\/SMAD4 signaling"],"prefix":"10.1016","volume":"449","author":[{"given":"Durdana","family":"Waseem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul Majid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihsan-Ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deeba N.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jat.1397","article-title":"The role of p44\/42 activation in tributyltin-induced inhibition of human natural killer cells: effects of MEK inhibitors","volume":"29","author":"Abraha","year":"2009","journal-title":"J. Appl. Toxicol."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0010","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.18632\/oncotarget.6625","article-title":"The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells","volume":"7","author":"Akhtar","year":"2016","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.taap.2022.116127_bb0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.drudis.2009.02.002","article-title":"Organometallic compounds in oncology: implications of novel organotins as antitumor agents","volume":"14","author":"Alama","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.taap.2022.116127_bb0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0003-9861(90)90610-B","article-title":"Tributyltin stimulates apoptosis in rat thymocytes","volume":"283","author":"Aw","year":"1990","journal-title":"Arch. Biochem. Biophys."},{"issue":"7","key":"10.1016\/j.taap.2022.116127_bb0025","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.ejmech.2011.04.005","article-title":"Synthesis, structural characterization and biological studies of the triphenyltin(IV) complex with 2-thiobarbituric acid","volume":"46","author":"Balas","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.taap.2022.116127_bb0030","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jinorgbio.2010.05.001","article-title":"Molecular basis of the interaction of novel tributyltin(IV) 2\/4-[(E)-2-(aryl)-1-diazenyl]benzoates endowed with an improved cytotoxic profile: synthesis, structure, biological efficacy and QSAR studies","volume":"104","author":"Basu Baul","year":"2010","journal-title":"J. Inorg. Biochem."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10637-009-9360-3","article-title":"Dibutyltin (IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes","volume":"29","author":"Basu Baul","year":"2011","journal-title":"Investig. New Drugs"},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10904-007-9159-7","article-title":"Synthesis, structural characterization, and initial evaluation as anticancer drugs of dibutyltin polyamines derived from various 4, 6-diaminopyrimidines","volume":"17","author":"Carraher","year":"2007","journal-title":"J. Inorg. Organomet. Polym. Mater."},{"issue":"11","key":"10.1016\/j.taap.2022.116127_bb0045","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1021\/pr5002516","article-title":"Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAFV600E mutant melanoma cells","volume":"13","author":"Cholewa","year":"2014","journal-title":"J. Proteome Res."},{"issue":"8","key":"10.1016\/j.taap.2022.116127_bb0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1940-6207.CAPR-15-0431","article-title":"Premalignancy in prostate cancer: rethinking what we know","volume":"9","author":"De Marzo","year":"2016","journal-title":"Cancer Prev. Res."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/bj1770461","article-title":"Triethyltin binding to cat haemoglobin. Evidence for two chemically distinct sites and a role for both histidine and cysteine residues","volume":"177","author":"Elliott","year":"1979","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.tiv.2015.02.007","article-title":"A comparison of the effects of tributyltin chloride and triphenyltin chloride on cell proliferation, proapoptotic p53, Bax, and antiapoptotic Bcl-2 protein levels in human breast cancer MCF-7 cell line","volume":"29","author":"Fickova","year":"2015","journal-title":"Toxicol. in Vitro"},{"issue":"5","key":"10.1016\/j.taap.2022.116127_bb0065","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4161\/cam.23840","article-title":"Integrins and metastasis","volume":"7","author":"Ganguly","year":"2013","journal-title":"Cell Adhes. Migr."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089349","article-title":"High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation","volume":"9","author":"Goel","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.taap.2022.116127_bb0080","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-05-2556","article-title":"Peroxisome proliferator\u2013activated receptor \u03b1 activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt","volume":"12","author":"Grabacka","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.taap.2022.116127_bb0085","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.1210\/en.2005-1129","article-title":"Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling","volume":"147","author":"Gr\u00fcn","year":"2006","journal-title":"Endocrinology."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0090","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-07-1929","article-title":"Androgen receptor and invasion in prostate cancer","volume":"68","author":"Hara","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/cbdd.12885","article-title":"Anionic chlorido(triphenyl)tin(IV) bearing N-phthaloylglycinato or 1,2,4-benzenetricarboxylato 1,2-anhydride ligands: potential cytotoxic and apoptosis-inducing agents against several types of cancer","volume":"89","author":"H\u00fcbner","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.taap.2022.116127_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.toxlet.2017.07.879","article-title":"Sn-and Ge-triorganometallics exert different cytotoxicity and modulation of migration in triple-negative breast cancer cell line MDA-MB-231","volume":"279","author":"Hunakova","year":"2017","journal-title":"Toxicol. Lett."},{"issue":"6","key":"10.1016\/j.taap.2022.116127_bb0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1039\/c0mt00007h","article-title":"Synthesis and biological applications of ionic triphenyltin (IV) chloride carboxylate complexes with exceptionally high cytotoxicity","volume":"2","author":"Kalu\u0111erovi\u0107","year":"2010","journal-title":"Metallomics."},{"issue":"11","key":"10.1016\/j.taap.2022.116127_bb0110","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/01.RES.0000046017.96083.34","article-title":"PPAR\u03b1 inhibits TGF-\u03b2\u2013induced \u03b25 integrin transcription in vascular smooth muscle cells by interacting with Smad4","volume":"91","author":"Kintscher","year":"2002","journal-title":"Circ. Res."},{"issue":"9\u201310","key":"10.1016\/j.taap.2022.116127_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1947601913507951","article-title":"Role of p38 MAP kinase signal transduction in solid tumors","volume":"4","author":"Koul","year":"2013","journal-title":"Genes Cancer."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.taap.2022.116127_bb0125","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1535-7163.MCT-16-0515","article-title":"Fisetin enhances chemotherapeutic effect of cabazitaxel against human prostate cancer cells","volume":"15","author":"Mukhtar","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.taap.2022.116127_bb0130","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","article-title":"Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma","volume":"25","author":"Nabors","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2131\/jts.33.269","article-title":"Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor","volume":"33","author":"Nakanishi","year":"2008","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.taap.2022.116127_bb0140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejmech.2012.11.023","article-title":"Tri- and diorganotin (IV) complexes of biologically important orotic acid: synthesis, spectroscopic studies, in vitro anticancer, DNA fragmentation, enzyme assays and in vivo antiinflammatory activities","volume":"59","author":"Nath","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.taap.2022.116127_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy\u2013an update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Design Developm. Ther."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.envres.2004.02.001","article-title":"Antiproliferative effect of butyltin in MCF-7 cells","volume":"96","author":"Nielsen","year":"2004","journal-title":"Environ. Res."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.toxlet.2004.10.009","article-title":"Some organotin compounds enhance histone acetyltransferase activity","volume":"155","author":"Osada","year":"2005","journal-title":"Toxicol. Lett."},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0002-9440(10)64228-9","article-title":"Prostatic intraepithelial neoplasia in genetically engineered mice","volume":"161","author":"Park","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2022.116127_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jinorgbio.2013.04.008","article-title":"Synthesis, chemical characterization and biological activity of new histone acetylation\/deacetylation specific inhibitors: a novel and potential approach to cancer therapy","volume":"125","author":"Pellerito","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.taap.2022.116127_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2008\/906542","article-title":"PPAR ligands as antitumorigenic and antiangiogenic agents","volume":"2008","author":"Pozzi","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.taap.2022.116127_bb0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cbi.2015.11.007","article-title":"New cytotoxic butyltin complexes with 2-sulfobenzoic acid: molecular interaction with lipid bilayers and DNA as well as in vitro anticancer activity","volume":"243","author":"Pruchnik","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.taap.2022.116127_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2016.07.006","article-title":"Dissecting major signaling pathways in prostate cancer development and progression: mechanisms and novel therapeutic targets","volume":"166","author":"Ramalingam","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119859","article-title":"Potent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in vitro and in vivo models","volume":"10","author":"Shabbir","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.taap.2022.116127_bb0195","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1021\/ic200635g","article-title":"Syntheses, molecular structures, electrochemical behavior, theoretical study, and antitumor activities of organotin (IV) complexes containing 1-(4-chlorophenyl)-1-cyclopentanecarboxylato ligands","volume":"50","author":"Shang","year":"2011","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.taap.2022.116127_bb0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejmech.2011.12.032","article-title":"Novel di-n-butyltin (IV) derivatives: synthesis, high levels of cytotoxicity in tumor cells and the induction of apoptosis in KB cancer cells","volume":"48","author":"Shang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F","article-title":"Activators of peroxisome proliferator activated receptor-\u03b1 partially inhibit mouse skin tumor promotion","volume":"29","author":"Thuillier","year":"2000","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jinorgbio.2009.12.006","article-title":"On the bioreactivity of triorganotin aminobenzoates. Investigation of trialkyl and triarylyltin (IV) esters of 3-amino and 4-aminobenzoic acids","volume":"104","author":"Tzimopoulos","year":"2010","journal-title":"J. Inorg. Biochem."},{"issue":"4","key":"10.1016\/j.taap.2022.116127_bb0215","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1530\/ERC-12-0285","article-title":"Current mouse and cell models in prostate cancer research","volume":"20","author":"Wu","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.taap.2022.116127_bb0220","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1172\/JCI71104","article-title":"Sustained activation of SMAD3\/SMAD4 by FOXM1 promotes TGF-\u03b2-dependent cancer metastasis","volume":"124","author":"Xue","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.taap.2022.116127_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090793","article-title":"Antitumor activity of di-n-butyl-(2, 6-difluorobenzohydroxamato) tin (IV) against human gastric carcinoma SGC-7901 cells via G2\/M cell cycle arrest and cell apoptosis","volume":"9","author":"Yunlan","year":"2014","journal-title":"PLoS One"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:02Z","timestamp":1758574862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X22002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"alternative-id":["S0041008X22002721"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2022.116127","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dibutylstannanediyl (2Z,2\u2032Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK\/PPAR\u03b1\/SMAD4 signaling","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2022.116127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116127"}}